Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A.

Abstract:

:Serum levels of cytokines and in vitro cytokine production by lymph node mononuclear cells (LNMC) were studied in four patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD) or AILD-type T cell lymphoma. An increased level of serum interleukin-6 (IL-6) was detected on initial diagnosis in both of two patients examined. Spontaneous production of IL-6 by LNMC was detected in all four patients studied. Immunosuppressive therapy with cyclosporin A (CsA) was attempted in a 68-year-old man, who was refractory to intensive combination chemotherapy. The increased level of IL-6 in this patient decreased to normal within 3 weeks of CsA administration and the patient became symptom-free. One and a half months later, the IL-6 level gradually increased along with clinical exacerbation. We also measured serum levels of IL-1 alpha, IL-2, IL-4, IFN-alpha, gamma and TNF-alpha in parallel with IL-6, but these factors were only sporadically detected. IL-6 production by LNMC was stimulated by IL-2 but inhibited by CsA. These observations suggest that IL-6 is one of the important cytokines to be involved in the pathophysiology of AILD and CsA is a useful reagent for relieving symptoms.

journal_name

Leukemia

journal_title

Leukemia

authors

Yamamura M,Honda M,Yamada Y,Itoyama T,Sohda H,Yubashi T,Momita S,Kamihira S,Ohmoto Y,Tomonaga M

subject

Has Abstract

pub_date

1996-09-01 00:00:00

pages

1504-8

issue

9

eissn

0887-6924

issn

1476-5551

journal_volume

10

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

    abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/leu.2010.205

    authors: Clappier E,Collette S,Grardel N,Girard S,Suarez L,Brunie G,Kaltenbach S,Yakouben K,Mazingue F,Robert A,Boutard P,Plantaz D,Rohrlich P,van Vlierberghe P,Preudhomme C,Otten J,Speleman F,Dastugue N,Suciu S,Benoit Y,B

    更新日期:2010-12-01 00:00:00

  • Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.

    abstract::The cyclin-dependent kinase inhibitors known as p15, p16, p18 and p19 have been suggested as candidates for tumor suppressor genes. The main genetic alterations are deletions (bi- or monoallelic) or 5' CpG island methylation of p15 and p16; very few cases or cell lines had p18 or p19 deletions or hypermethylation. Hyp...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401043

    authors: Drexler HG

    更新日期:1998-06-01 00:00:00

  • Efficient gene transfer in CLL by mRNA electroporation.

    abstract::Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405007

    authors: Van Bockstaele F,Pede V,Naessens E,Van Coppernolle S,Van Tendeloo V,Verhasselt B,Philippé J

    更新日期:2008-02-01 00:00:00

  • The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

    abstract::The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.233

    authors: Zhan H,Lin CHS,Segal Y,Kaushansky K

    更新日期:2018-02-01 00:00:00

  • IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.

    abstract::Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dilloo D,Hanenberg H,Lion T,Burdach S

    更新日期:1995-03-01 00:00:00

  • The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells.

    abstract::The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Fenstermaker RA,Capala J,Barth RF,Hujer A,Kung HJ,Kaetzel DM Jr

    更新日期:1995-10-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.225

    authors: Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期:2017-02-01 00:00:00

  • Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.

    abstract::Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.295

    authors: Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

    更新日期:2009-02-01 00:00:00

  • Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

    abstract::Hemizygous deletions are common molecular abnormalities in cancer. In some cases, these deletions highlight chromosomal loci containing tumor suppressor genes that undergo homozygous inactivation. In other cases, hemizygous deletions cause disease by allelic insufficiency for one or more genes. As the intact allele ha...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.53

    authors: Ebert BL

    更新日期:2009-07-01 00:00:00

  • PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.329

    authors: Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

    更新日期:2013-04-01 00:00:00

  • Effects of clinical combinations of antileukemic drugs on DNA ligase from human thymocytes and normal, stimulated, or leukemic lymphocytes.

    abstract::Human DNA ligase was purified from different kinds of immunocompetent cells: thymocytes, normal and stimulated lymphocytes, blasts from ALL (Burkitt and non-T, non-B) and ANLL (M1, M2, and M5). Based upon the protocol for the treatment of these leukemias, the purified enzymes were assayed in the presence of routinely ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lamballe F,Maniey D,Boscher MY,Fauchet R,le Prise PY,David JC

    更新日期:1988-06-01 00:00:00

  • Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia.

    abstract::The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis. Relapse-free survival remains li...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401648

    authors: Anasetti C

    更新日期:2000-03-01 00:00:00

  • Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

    abstract::Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome 5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.296

    authors: Matsuoka A,Tochigi A,Kishimoto M,Nakahara T,Kondo T,Tsujioka T,Tasaka T,Tohyama Y,Tohyama K

    更新日期:2010-04-01 00:00:00

  • The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.

    abstract::The chromosomal inversion (16)(p13q22), which is associated with the M4-eosinophilia subtype of human acute myeloid leukemia, causes the fusion of two distinct genes. The polypeptide encoded by the chimeric gene, PEBP2p/CBFp-SMMHC, retains the ability to interact with, and dominantly interfere with the function of pro...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401821

    authors: Kanto S,Chiba N,Tanaka Y,Fujita S,Endo M,Kamada N,Yoshikawa K,Fukuzaki A,Orikasa S,Watanabe T,Satake M

    更新日期:2000-07-01 00:00:00

  • RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.

    abstract::Runt-related transcription factor 1 (RUNX1) is essential for normal hematopoiesis. RUNX1 mutations have rarely been reported in chronic myelomonocytic leukemia (CMML). We examined RUNX1 mutations in 81 patients with CMML at initial diagnosis. Mutational analysis was performed on bone marrow samples by direct sequencin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.48

    authors: Kuo MC,Liang DC,Huang CF,Shih YS,Wu JH,Lin TL,Shih LY

    更新日期:2009-08-01 00:00:00

  • Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.

    abstract::In patients with hematologic malignancy, invasive aspergillosis continues to be associated with high mortality even when treated with conventional antifungal therapy. To investigate novel antifungal agents, we compared 53 patients who received posaconazole salvage therapy to 52 contemporary control patients who receiv...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.leu.2405065

    authors: Raad II,Hanna HA,Boktour M,Jiang Y,Torres HA,Afif C,Kontoyiannis DP,Hachem RY

    更新日期:2008-03-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract::Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.246

    authors: Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期:2010-02-01 00:00:00

  • Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

    abstract::p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53-MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(14;18)(q32;q21), BC...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.28

    authors: Drakos E,Singh RR,Rassidakis GZ,Schlette E,Li J,Claret FX,Ford RJ Jr,Vega F,Medeiros LJ

    更新日期:2011-05-01 00:00:00

  • Proteomic analysis of childhood leukemia.

    abstract::Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing differen...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2403897

    authors: Hegedus CM,Gunn L,Skibola CF,Zhang L,Shiao R,Fu S,Dalmasso EA,Metayer C,Dahl GV,Buffler PA,Smith MT

    更新日期:2005-10-01 00:00:00

  • Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting.

    abstract::The karyotype of a boy with acute lymphoblastic leukemia (ALL) presenting with numerical and structural chromosome aberrations as determined by Giemsa-banding was further investigated using chromosome painting (CP). A translocation t(11;18)(q23;q21) was verified by this approach, and gain of chromosome 21 material due...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rieder H,Kolbus U,Koop U,Ludwig WD,Stollmann-Gibbels B,Fonatsch C

    更新日期:1993-10-01 00:00:00

  • Human cord blood long-term engrafting cells are CD34+ CD38-.

    abstract::There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/beta2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402878

    authors: Ishikawa F,Livingston AG,Minamiguchi H,Wingard JR,Ogawa M

    更新日期:2003-05-01 00:00:00

  • Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells.

    abstract::CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404312

    authors: Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

    更新日期:2006-09-01 00:00:00

  • Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.

    abstract::Children with acute lymphoblastic leukemia (ALL) with > or = 0.01% leukemic cells in the bone marrow after remission induction are at a greater risk of relapse. The most promising methods of detecting minimal residual disease (MRD) are flow cytometric identification of leukemia-associated immunophenotypes and polymera...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401459

    authors: Neale GA,Coustan-Smith E,Pan Q,Chen X,Gruhn B,Stow P,Behm FG,Pui CH,Campana D

    更新日期:1999-08-01 00:00:00

  • The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

    abstract::Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0486-9

    authors: Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

    更新日期:2020-01-01 00:00:00

  • AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

    abstract::The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.33

    authors: Stankiewicz MJ,Crispino JD

    更新日期:2013-06-01 00:00:00

  • Hypermethylation of the calcitonin gene in the myelodysplastic syndromes.

    abstract::It is well documented that the calcitonin gene area in the short arm of chromosome 11 is hypermethylated in most acute leukemias as well as in chronic lymphatic leukemia. In contrast, the gene is normally methylated during the chronic phase of the chronic myeloid leukemia but turns hypermethylated as the disease escal...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ihalainen J,Pakkala S,Savolainen ER,Jansson SE,Palotie A

    更新日期:1993-02-01 00:00:00

  • The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.

    abstract::Resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Resistance to this class of drugs may (partly) be reversed by modulating agents, as has been demonstrated in a variety of cell lines. However, it is unknown which modulators may be of clinical benefit in childh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401035

    authors: den Boer ML,Pieters R,Kazemier KM,Janka-Schaub GE,Henze G,Veerman AJ

    更新日期:1998-06-01 00:00:00

  • Molecular analyses of chromosome 12 in chronic lymphocytic leukemia.

    abstract::Trisomy 12 is the most common chromosomal aberration in chronic B lymphocytic leukemia (B-CLL). In this study we have investigated trisomy 12 and posed two major questions: (a) What is the origin of the third copy of chromosome 12? and (b) What is the proportion of trisomy 12 cells in malignant clones with this aberra...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Einhorn S,Burvall K,Juliusson G,Gahrton G,Meeker T

    更新日期:1989-12-01 00:00:00

  • Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

    abstract::The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.136

    authors: Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

    更新日期:2016-12-01 00:00:00